In fact, our search confirmed a substantially high rate of grade 3/4 neutropenia (51–91%) observed in SCLC patients treated with etoposide/platinum chemotherapy given the fact that G-CSF use has been allowed in 3 out of nine trials. This evidence concerns the gene CSF3 and neutropenia.